ライフサイエンスコーパス: primary biliary cirrhosis

1 cholangitis (PBC, previously referred to as primary biliary cirrhosis).

2 coholic hepatitis, autoimmune hepatitis, and primary biliary cirrhosis.

3 atory response in the dnTGF-betaRII model of primary biliary cirrhosis.

4 ly phases of small bile duct injury found in primary biliary cirrhosis.

5 er murine models as well as in patients with primary biliary cirrhosis.

6 antigen of relevance for the pathogenesis of primary biliary cirrhosis.

7 lic liver disease, autoimmune hepatitis, and primary biliary cirrhosis.

8 gger that may break immunologic tolerance in primary biliary cirrhosis.

9 both of which are targets for destruction in primary biliary cirrhosis.

10 e complex (PDC)-E2, the major autoantigen of primary biliary cirrhosis.

11 PDC-E2) is the immunodominant autoantigen of primary biliary cirrhosis.

12 iral nucleotide sequences from patients with primary biliary cirrhosis.

13 evidence to suggest a viral association with primary biliary cirrhosis.

14 study was to clarify the efficacy of UDCA in primary biliary cirrhosis.

15 ody identified in about 95% of patients with primary biliary cirrhosis.

16 oms, and/or liver histology in patients with primary biliary cirrhosis.

17 troviruses play a part in the development of primary biliary cirrhosis.

18 ts with features of autoimmune hepatitis and primary biliary cirrhosis.

19 at UDCA improves transplant-free survival in primary biliary cirrhosis.

20 hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis.

21 granulation and reduces eosinophil counts in primary biliary cirrhosis.

22 olic liver disease, HIV/HCV co-infection and primary biliary cirrhosis.

23 dies and liver inflammation similar to human primary biliary cirrhosis.

24 (1), and primary pulmonary hypertension with primary biliary cirrhosis (1).

25 enic cirrhosis (1), hemochromatosis (1), and primary biliary cirrhosis (1).

26 IAP), on serum samples from 77 patients with primary biliary cirrhosis, 126 patients with chronic liv

27 ty was found in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with

28 or LAR were in seronegative hepatitis (17%), primary biliary cirrhosis (16%), and primary sclerosing

29 ding syndromes with autoimmune hepatitis and primary biliary cirrhosis (7%) or primary sclerosing cho

30 s transplanted for other indications such as primary biliary cirrhosis (8.2%; P<0.05), primary sclero

31 osis: They were most common in patients with primary biliary cirrhosis (86% [43 of 50]) and least com

32 ed a double-blind study of 165 patients with primary biliary cirrhosis (95% women) and levels of alka

33 ortant therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic live

34 ed these mutants for reactivities against 60 primary biliary cirrhosis and 103 control sera.

35 of PHB1 is markedly reduced in patients with primary biliary cirrhosis and biliary atresia or with Al

36 imary sclerosing cholangitis, in addition to primary biliary cirrhosis and biliary atresia.

37 In the vanishing bile duct syndromes (VBDS), primary biliary cirrhosis and chronic allograft rejectio

38 hing between autoimmune liver diseases, with primary biliary cirrhosis and its antimitochondrial-nega

39 mechanisms, may precipitate autoimmunity in primary biliary cirrhosis and other autoimmune diseases.

40 P antibody reactivity found in patients with primary biliary cirrhosis and other biliary disorders ma

41 ls in intrahepatic cholestasis of pregnancy, primary biliary cirrhosis and primary sclerosing cholang

42 nti-inflammatory effects and to benefit both primary biliary cirrhosis and primary sclerosing cholang

43 t also a surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholang

44 In contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholang

45 ith development of the autoimmune conditions primary biliary cirrhosis and rheumatoid arthritis.

46 to 12 years of treatment showed few signs of primary biliary cirrhosis and, in 3 patients, were close

47 is, alcohol-related), (2) cholestatic (e.g., primary biliary cirrhosis), and (3) cryptogenic.

48 ype 1 autoimmune hepatitis, 37 patients with primary biliary cirrhosis, and 26 patients with primary

49 pus erythematosus (SLE), Sjogren's syndrome, primary biliary cirrhosis, and active hepatitis.

50 r in patients with hepatitis C, hepatitis B, primary biliary cirrhosis, and autoimmune hepatitis.

51 d might also influence autoimmune hepatitis, primary biliary cirrhosis, and cholangiocarcinogenesis.

52 with biliary atresia, hepatitis BC, alcohol, primary biliary cirrhosis, and fulminant hepatitis.

53 l for end-stage liver disease 15-34, without primary biliary cirrhosis, and not on life support befor

54 t-time recipients with a MELD 15-34, without primary biliary cirrhosis, and not on life support prior

55 c regression showed that younger recipients, primary biliary cirrhosis, and previous graft loss were

56 iver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholan

57 s for intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, and primary sclerosing cholan

58 insight into the pathogenesis of gallstones, primary biliary cirrhosis, and primary sclerosing cholan

59 r assessing prognosis in biliary atresia and primary biliary cirrhosis; and important clinical trials

60 ursodeoxycholic acid) benefits patients with primary biliary cirrhosis, another cholestatic liver dis

61 tibodies (AMAs), the serological hallmark of primary biliary cirrhosis, are directed against the lipo

62 patitis, primary sclerosing cholangitis, and primary biliary cirrhosis as a group had a tendency towa

63 id (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease pro

64 id (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease pro

65 including primary sclerosing cholangitis and primary biliary cirrhosis, but not with single-nucleotid

66 ved biochemical test results and symptoms in primary biliary cirrhosis, but the response to methotrex

67 at lymph node homogenates from patients with primary biliary cirrhosis can induce autoantigen express

68 Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and

69 ctors play a key role in the pathogenesis of primary biliary cirrhosis, cholangiocarcinoma, liver cys

70 3 gene-spanning haplotype is associated with primary biliary cirrhosis, demonstrating the nuance of s

71 Patients with primary biliary cirrhosis develop progressive ductopenia

72 iology, pathogenesis, and natural history of primary biliary cirrhosis, discuss management of the dis

73 carcinoma, alcohol cirrhosis, hepatitis C or primary biliary cirrhosis, donor age 40 years or younger

74 genesis, clinical features, and treatment of primary biliary cirrhosis, drug-induced cholestasis, and

75 Individuals with autoimmune hepatitis and primary biliary cirrhosis entered remission during corti

76 is, new understanding of the pathogenesis of primary biliary cirrhosis, familial intrahepatic cholest

77 erosing cholangitis, cellular rejection, and primary biliary cirrhosis, four liver diseases affecting

78 Primary biliary cirrhosis frequently progresses despite

79 The typical course of primary biliary cirrhosis has changed substantially with

80 pothesis of a bacterial role in the cause of primary biliary cirrhosis has received recent attention,

81 ave found that the majority of patients with primary biliary cirrhosis have both RT-PCR and immunohis

82 otype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals b

83 autoimmune cholangitis with similarities to primary biliary cirrhosis in humans.

84 at accurately predict the natural history of primary biliary cirrhosis in individuals.

85 rimary sclerosing cholangitis, and recurrent primary biliary cirrhosis in terms of the clinical entit

86 one third of those previously described for primary biliary cirrhosis in the same population.

87 teins was found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with

88 ckground increase the severity of autoimmune primary biliary cirrhosis induced by infection with Novo

89 Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and

90 Primary biliary cirrhosis is a chronic cholestatic liver

91 Primary biliary cirrhosis is a chronic cholestatic liver

92 Primary biliary cirrhosis is a chronic inflammatory dise

93 Primary biliary cirrhosis is an immune-mediated chronic

94 pathogenesis of the autoimmune liver disease primary biliary cirrhosis is breakdown of T-cell self-to

95 Identification of primary biliary cirrhosis is important, because effectiv

96 The serological hallmark of primary biliary cirrhosis is the antimitochondrial antib

97 In some patients, primary biliary cirrhosis may remit in response to metho

98 controls (n = 10), and disease controls with primary biliary cirrhosis (n = 10).

99 (22.4%) for recurrence of original disease: primary biliary cirrhosis (n= 19), sclerosing cholangiti

100 ell as in serum samples of disease controls (primary biliary cirrhosis; n = 22).

101 , intrahepatic cholestasis of pregnancy, and primary biliary cirrhosis; new information for assessing

102 be female, white, and have the diagnoses of primary biliary cirrhosis or cryptogenic cirrhosis than

103 insulin resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic steatohepatiti

104 significantly higher than from patients with primary biliary cirrhosis or nonalcoholic steatohepatiti

105 ase, and underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis were

106 Underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis, num

107 patients with alcohol-induced liver disease, primary biliary cirrhosis, or chronic hepatitis C.

108 utoimmune hepatitis (P = 0.01, HR = 4.2) and primary biliary cirrhosis (P = 0.04, HR = 2).

109 ctions of primary sclerosing cholangitis and primary biliary cirrhosis patient liver samples.

110 d in cholangiocytes from control patients or primary biliary cirrhosis patients nor in hepatocytes fr

111 Compared to healthy controls or primary biliary cirrhosis patients, PBMCs from PSC patie

112 6), (3) patients with cirrhosis secondary to primary biliary cirrhosis (PBC) (n = 6), and (4) healthy

113 s' follow-up and only included patients with primary biliary cirrhosis (PBC) according to established

114 noclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete respon

115 PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before t

116 gene and protein expression in the liver of primary biliary cirrhosis (PBC) and controls.

117 Comparisons were made between patients with primary biliary cirrhosis (PBC) and hepatocellular cirrh

118 xamined temporal changes in the incidence of primary biliary cirrhosis (PBC) and investigated associa

119 epatocellular carcinoma (HCC) development in primary biliary cirrhosis (PBC) and its effects on patie

120 is invoked as a strong component underlying primary biliary cirrhosis (PBC) and other autoimmune dis

121 Primary biliary cirrhosis (PBC) and primary sclerosing c

122 ent of cholestatic liver diseases, including primary biliary cirrhosis (PBC) and primary sclerosing c

123 e patients who underwent transplantation for primary biliary cirrhosis (PBC) and primary sclerosing c

124 Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing c

125 Primary biliary cirrhosis (PBC) and primary sclerosing c

126 ion in 50 consecutive patients with advanced primary biliary cirrhosis (PBC) and primary sclerosing c

127 trument was administered in 96 patients with primary biliary cirrhosis (PBC) and primary sclerosing c

128 ntation among 447 transplant recipients with primary biliary cirrhosis (PBC) and primary sclerosing c

129 rial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA

130 Sera from patients with primary biliary cirrhosis (PBC) are characterized by the

131 iver transplantation for classical end-stage primary biliary cirrhosis (PBC) are described, who went

132 Autoreactive T-cell responses seen in primary biliary cirrhosis (PBC) are typically of the Th1

133 recent study we showed that in patients with primary biliary cirrhosis (PBC) being positive or negati

134 on the efficacy of liver transplantation in primary biliary cirrhosis (PBC) by demonstrating that th

135 They were distinguished from primary biliary cirrhosis (PBC) by higher serum levels o

136 Patients with primary biliary cirrhosis (PBC) characteristically show

137 PSC and LTx cohort patients and primary biliary cirrhosis (PBC) control patients were ge

138 s of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year ran

139 sed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized

140 alitative studies suggest that patients with primary biliary cirrhosis (PBC) experience significant p

141 ment of cholestatic liver diseases including primary biliary cirrhosis (PBC) for which it has a posit

142 Patients with primary biliary cirrhosis (PBC) frequently experience si

143 We genotyped 2,861 cases of primary biliary cirrhosis (PBC) from the UK PBC Consorti

144 Primary biliary cirrhosis (PBC) has a complex clinical p

145 al association between cigarette smoking and primary biliary cirrhosis (PBC) has been demonstrated.

146 Our understanding of primary biliary cirrhosis (PBC) has been significantly e

147 Unlike other autoimmune liver diseases, primary biliary cirrhosis (PBC) has never been reported

148 The epidemiology of primary biliary cirrhosis (PBC) has not been studied sys

149 Controversy exists as to whether people with primary biliary cirrhosis (PBC) have an increased risk o

150 Patients with primary biliary cirrhosis (PBC) have autoantibodies that

151 the HLA locus, six genetic risk factors for primary biliary cirrhosis (PBC) have been identified in

152 Patients with primary biliary cirrhosis (PBC) have both serologic and

153 Primary biliary cirrhosis (PBC) illustrates this paradig

154 Primary biliary cirrhosis (PBC) is a chronic cholestatic

155 Primary biliary cirrhosis (PBC) is a chronic cholestatic

156 Primary biliary cirrhosis (PBC) is a chronic, cholestati

157 Primary biliary cirrhosis (PBC) is a classical autoimmun

158 Primary biliary cirrhosis (PBC) is a disease of unknown

159 Primary biliary cirrhosis (PBC) is a disease with geneti

160 Primary biliary cirrhosis (PBC) is a liver disease chara

161 Primary biliary cirrhosis (PBC) is a progressive autoimm

162 Primary biliary cirrhosis (PBC) is a progressive cholest

163 Primary biliary cirrhosis (PBC) is an autoimmune disease

164 Primary biliary cirrhosis (PBC) is an autoimmune disease

165 Primary biliary cirrhosis (PBC) is an autoimmune disease

166 Primary biliary cirrhosis (PBC) is an autoimmune disease

167 Primary biliary cirrhosis (PBC) is an autoimmune liver d

168 Primary biliary cirrhosis (PBC) is an autoimmune liver d

169 Primary biliary cirrhosis (PBC) is an autoimmune liver d

170 Primary biliary cirrhosis (PBC) is an autoimmune liver d

171 Primary biliary cirrhosis (PBC) is an organ-specific aut

172 Primary biliary cirrhosis (PBC) is an uncommon chronic c

173 Primary biliary cirrhosis (PBC) is characterized by an i

174 Primary biliary cirrhosis (PBC) is characterized by anti

175 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by auto

176 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by the

177 Primary biliary cirrhosis (PBC) is considered a model au

178 Primary biliary cirrhosis (PBC) is considered a model au

179 antimitochondrial antibody (AMA) response in primary biliary cirrhosis (PBC) is directed against the

180 chondrial antibody response in patients with primary biliary cirrhosis (PBC) is directed against the

181 The etiology of primary biliary cirrhosis (PBC) is far from clear.

182 Primary biliary cirrhosis (PBC) is generally a slowly pr

183 f patients with the autoimmune liver disease primary biliary cirrhosis (PBC) is increasing, although

184 The development of liver fibrosis markers in primary biliary cirrhosis (PBC) is needed to facilitate

185 Primary biliary cirrhosis (PBC) is often considered to b

186 Primary biliary cirrhosis (PBC) is sometimes diagnosed b

187 The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly direc

188 aracteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-

189 The serological hallmark of primary biliary cirrhosis (PBC) is the presence of pyruv

190 A major enigma of primary biliary cirrhosis (PBC) is the selective targeti

191 The cause of primary biliary cirrhosis (PBC) is unclear.

192 E2), a ubiquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained.

193 Although the etiology and mechanism of primary biliary cirrhosis (PBC) is unknown, growing evid

194 ents with features otherwise consistent with primary biliary cirrhosis (PBC) lack antimitochondrial a

195 Patients with primary biliary cirrhosis (PBC) may be at increased risk

196 in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing ch

197 ablished therapy for patients with end-stage primary biliary cirrhosis (PBC) or primary sclerosing ch

198 We studied the outcome of 436 patients with primary biliary cirrhosis (PBC) or primary sclerosing ch

199 More than 95% of primary biliary cirrhosis (PBC) patients have detectable

200 BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have

201 mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly hi

202 Primary biliary cirrhosis (PBC) recurs in the allograft

203 ponsible for organ-specific tissue damage in primary biliary cirrhosis (PBC) remain an enigma, it has

204 Although the etiology of primary biliary cirrhosis (PBC) remains unknown, environ

205 olved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.

206 Autoimmune diseases such as primary biliary cirrhosis (PBC) result from failure in t

207 A significant proportion of patients with primary biliary cirrhosis (PBC) suffer from severe fatig

208 ta in both humans and murine models of human primary biliary cirrhosis (PBC) suggest that activated T

209 The incidence of primary biliary cirrhosis (PBC) varies widely between re

210 Primary biliary cirrhosis (PBC) was first described in t

211 The treatment of primary biliary cirrhosis (PBC) with conventional immuno

212 samples were collected from 91 patients with primary biliary cirrhosis (PBC), 28 immediate relatives,

213 Primary biliary cirrhosis (PBC), a chronic autoimmune li

214 noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected pati

215 atic biliary epithelial cells from explanted primary biliary cirrhosis (PBC), and control liver using

216 coholic steatohepatitis (NASH), hepatitis B, primary biliary cirrhosis (PBC), and primary sclerosing

217 cer incidence of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing

218 urred in patients who subsequently developed primary biliary cirrhosis (PBC), and thus may be involve

219 ctive medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show

220 fe and effective treatment for patients with primary biliary cirrhosis (PBC), but the cost of this dr

221 he bile duct epithelium during the course of primary biliary cirrhosis (PBC), but the importance of I

222 cts are found in the livers of subjects with primary biliary cirrhosis (PBC), but the mechanisms invo

223 ome are sometimes exhibited in patients with primary biliary cirrhosis (PBC), but the postulated auto

224 The immunodominant autoantigen in primary biliary cirrhosis (PBC), E2 components of pyruva

225 Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early

226 destruction of biliary epithelia observed in primary biliary cirrhosis (PBC), graft-versus-host disea

227 autoimmune cholangitis that resembles human primary biliary cirrhosis (PBC), including antimitochond

228 ermore, we show that SNPs conferring risk to primary biliary cirrhosis (PBC), inflammatory bowel dise

229 In primary biliary cirrhosis (PBC), it has been postulated

230 In primary biliary cirrhosis (PBC), patients develop a mult

231 ified in the nonviral chronic liver diseases primary biliary cirrhosis (PBC), primary sclerosing chol

232 The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial r

233 In primary biliary cirrhosis (PBC), the major autoepitope r

234 the serum of more than 95% of patients with primary biliary cirrhosis (PBC), the major epitope being

235 To further characterize the genetic basis of primary biliary cirrhosis (PBC), we genotyped 2426 PBC p

236 toantibodies (AMAs) closely resembling human primary biliary cirrhosis (PBC).

237 ary sclerosing cholangitis (PSC), but seldom primary biliary cirrhosis (PBC).

238 body recognition and epitope modification in primary biliary cirrhosis (PBC).

239 rs with increased frequency in patients with primary biliary cirrhosis (PBC).

240 lvement in the response to biliary injury in primary biliary cirrhosis (PBC).

241 n who had several clinical manifestations of primary biliary cirrhosis (PBC).

242 there is a significant genetic component to primary biliary cirrhosis (PBC).

243 oantibodies, has been extensively studied in primary biliary cirrhosis (PBC).

244 s as causative agents in the pathogenesis of primary biliary cirrhosis (PBC).

245 in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC).

246 ne loss is a well-recognized complication of primary biliary cirrhosis (PBC).

247 MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC).

248 been recognized as a serological hallmark of primary biliary cirrhosis (PBC).

249 ptibility and environmental factors leads to primary biliary cirrhosis (PBC).

250 uman mouse mammary tumor virus (MMTV) causes primary biliary cirrhosis (PBC).

251 ase) were elevated in all indications except primary biliary cirrhosis (PBC).

252 recognized by antimitochondrial Abs (AMA) in primary biliary cirrhosis (PBC).

253 ve been proposed as immunologic triggers for primary biliary cirrhosis (PBC).

254 be involved in generation of autoepitopes in primary biliary cirrhosis (PBC).

255 eactive T lymphocytes in the pathogenesis of primary biliary cirrhosis (PBC).

256 od and liver from controls and patients with primary biliary cirrhosis (PBC).

257 uct loss that characterizes diseases such as primary biliary cirrhosis (PBC).

258 ctive medical therapy for most patients with primary biliary cirrhosis (PBC).

259 fective treatment for patients with advanced primary biliary cirrhosis (PBC).

260 gments corresponding to the ducts damaged in primary biliary cirrhosis (PBC).

261 an important criterion for the diagnosis of primary biliary cirrhosis (PBC).

262 s assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

263 been associated with the etiopathogenesis of primary biliary cirrhosis (PBC).

264 disease (SIR 2.78); five of these cases had primary biliary cirrhosis (PBC).

265 t have opposing effects on susceptibility to primary biliary cirrhosis (PBC).

266 ctular disease that strongly resembles human primary biliary cirrhosis (PBC).

267 fractures is a complication in patients with primary biliary cirrhosis (PBC).

268 Liver biopsy is important for diagnosing primary biliary cirrhosis (PBC).

269 els described with features similar to human primary biliary cirrhosis (PBC).

270 d blood mononuclear cells from patients with primary biliary cirrhosis (PBC).

271 autoimmune biliary disease (ABD) resembling primary biliary cirrhosis (PBC).

272 ificantly influence complex diseases such as primary biliary cirrhosis (PBC).

273 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosin

274 as queried for adults receiving first LT for primary biliary cirrhosis (PBC; n=3052), primary scleros

275 ease from biliary causes of cirrhosis (e.g., primary biliary cirrhosis [PBC], and primary sclerosing

276 Primary biliary cirrhosis, primary sclerosing cholangiti

277 011) queried for deceased donor first LT for primary biliary cirrhosis, primary sclerosing cholangiti

278 nic pruritus due to liver disease (including primary biliary cirrhosis, primary sclerosing cholangiti

279 genesis, clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangiti

280 genesis, clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangiti

281 of specific cholestatic syndromes including primary biliary cirrhosis, primary sclerosing cholangiti

282 stasis, and clinical trials of therapies for primary biliary cirrhosis, primary sclerosing cholangiti

283 Additionally, the diagnoses of primary biliary cirrhosis, primary sclerosing cholangiti

284 , hepatitis C with hepatocellular carcinoma, primary biliary cirrhosis, primary sclerosing cholangiti

285 roups were Laennec's cirrhosis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangiti

286 VCAM-1 was detected on BDs in CLDs (primary biliary cirrhosis, primary sclerosing cholangiti

287 ents with cholestatic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangiti

288 The precise aetiopathogenesis of primary biliary cirrhosis remains unknown, although dysr

289 litis (rg = 0.11 +/- 0.04, P = 4.05 x 10-3), primary biliary cirrhosis (rg = 0.13 +/- 0.05, P = 3.98

290 disease, Crohn's disease, Addison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenil

291 Recurrent primary biliary cirrhosis (RPBC) is a histologic diagnos

292 iseases, including scleroderma, thyroiditis, primary biliary cirrhosis, Sjogren syndrome, systemic lu

293 address the role of B cells in this model of primary biliary cirrhosis, we bred B cell-deficient mice

294 also develop the phenotypic manifestation of primary biliary cirrhosis when cocultivated in serial pa

295 ontributes to breakdown of self-tolerance in primary biliary cirrhosis, whereas those of DR1101 promo

296 randomized controlled trial of patients with primary biliary cirrhosis who had an inadequate response

297 ase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses t

298 -five patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphata

299 Patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphata

300 targets for autoreactive immune responses in primary biliary cirrhosis, with lipoic acid itself formi